Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies…
<!-- Name:DistributionId Value:8841596 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Capsids
Sarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing…
-Following internal corroboration of published results on the MyoAAV platform, Sarepta secures exclusive license for Duchenne muscular dystrophy, plus four additional neuromuscular and…
Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across…
VCAP-102 capsid achieved respective 60-fold and 50-fold improvements in brain transduction in non-human primates and mice compared to conventional AAV9 capsids with IV dosing Data…
Atsena Therapeutics Unveils XLRS Gene Therapy Program Leveraging Novel Spreading…
Subretinal delivery of RS1 using AAV capsid that spreads laterally beyond the injection site overcomes challenges associated with intravitreal delivery DURHAM, N.C., Oct. 18, 2021 (GLOBE…